CYCN RSI Chart
Last 7 days
6.8%
Last 30 days
1.6%
Last 90 days
-13.9%
Trailing 12 Months
-47.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 |
2022 | 4.6M | 1.9M | 1.6M | 297.0K |
2021 | 2.7M | 3.1M | 3.5M | 3.9M |
2020 | 4.0M | 3.4M | 2.8M | 2.3M |
2019 | 0 | 0 | 0 | 4.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 01, 2024 | graul regina margaret | acquired | - | - | 50,000 | president |
Jan 01, 2024 | hecht peter m | acquired | - | - | 15,000 | - |
Dec 01, 2023 | hecht peter m | acquired | - | - | 15,000 | - |
Nov 30, 2023 | hyman steven | acquired | - | - | 20,000 | - |
Nov 30, 2023 | mcguire terrance | acquired | - | - | 5,000 | - |
Nov 30, 2023 | desouza errol b | acquired | - | - | 50,000 | - |
Nov 30, 2023 | hecht peter m | acquired | - | - | 20,000 | - |
Aug 09, 2023 | mcguire terrance | sold | -27.16 | 3.395 | -8.00 | - |
May 19, 2023 | hecht peter m | acquired | 1,953,000 | 8.68 | 225,000 | chief executive officer |
Jun 03, 2021 | mcguire terrance | bought | 289,633 | 3.12 | 92,831 | - |
Which funds bought or sold CYCN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | unchanged | - | -21,344 | 444,656 | 0.01% |
May 15, 2024 | MORGAN STANLEY | reduced | -7.02 | -261 | 2,077 | -% |
May 15, 2024 | Slate Path Capital LP | unchanged | - | -53,682 | 1,145,220 | 0.02% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 106 | 106 | -% |
May 15, 2024 | TYNDALL CAPITAL PARTNERS L P | added | 0.21 | -23,551 | 527,286 | 100.00% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | - | 3.00 | -% |
May 15, 2024 | Royal Bank of Canada | added | 6.67 | - | 1,000 | -% |
May 13, 2024 | FMR LLC | reduced | -0.32 | -26,098 | 519,447 | -% |
May 13, 2024 | UBS Group AG | added | 13.29 | 613 | 8,077 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 2.63 | -2,054 | 102,694 | -% |
Unveiling Cyclerion Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cyclerion Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Cyclerion Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Revenue | - | - | - | 7,564,000 | 5,042,667 | 2,521,333 | - | 306,000 | 711,000 | 533,000 | 348,000 | 3,000,000 | 1,566,500 | 133,000 | 400,000 | 749,000 | 1,014,000 | 1,206,000 | 1,398,000 | 1,628,000 |
Operating Expenses | -9.9% | 1,618,000 | 1,795,000 | 6,015,000 | 7,042,000 | -4,330,000 | 4,518,000 | 13,739,000 | 13,695,000 | 14,871,000 | 11,633,000 | 19,176,000 | 13,457,000 | 19,357,000 | 22,180,000 | 20,421,000 | 21,603,000 | 28,067,000 | 29,414,000 | 34,682,000 |
S&GA Expenses | -100.0% | - | 573,000 | 2,131,000 | 3,269,000 | 2,780,000 | 3,104,000 | 3,521,000 | 3,952,000 | 4,413,000 | 4,601,000 | 6,241,000 | 5,365,000 | 7,265,000 | 8,033,000 | 6,627,000 | 6,891,000 | 7,385,000 | 7,119,000 | 8,923,000 |
R&D Expenses | 83.3% | 44,000 | 24,000 | 580,000 | 3,773,000 | -7,110,000 | 1,414,000 | 10,218,000 | 9,743,000 | 10,458,000 | 7,032,000 | 12,054,000 | 8,092,000 | 12,092,000 | 13,703,000 | 13,794,000 | 16,825,000 | 20,682,000 | 22,295,000 | 25,759,000 |
EBITDA Margin | - | - | - | - | -31.77 | -31.74 | -38.89 | -30.44 | -11.64 | -12.98 | -21.62 | -24.48 | -28.01 | -32.89 | -32.91 | -25.81 | -21.67 | -26.56 | -18.63 | -17.36 |
EBT Margin | - | - | - | - | -31.78 | -31.78 | -38.98 | -30.87 | -11.83 | -13.10 | -22.04 | -24.94 | -28.74 | -33.89 | -33.59 | -26.37 | -22.17 | -27.16 | -19.04 | -17.70 |
Net Income | 9.0% | -1,542,000 | -1,694,000 | 7,566,000 | -6,954,000 | -7,216,000 | -10,496,000 | -13,388,000 | -12,978,000 | -13,998,000 | -11,290,000 | -16,182,000 | -6,954,000 | -19,228,000 | -18,812,000 | -19,534,000 | -20,228,000 | -26,055,500 | -27,317,000 | -32,254,000 |
Net Income Margin | 102.8% | 0.50 | -17.72 | -36.31 | -128 | -148 | -32.81 | -27.21 | -11.86 | -12.28 | -15.20 | -19.61 | - | - | - | - | - | - | - | - |
Free Cashflow | -21.4% | -1,871,000 | -1,541,000 | -6,935,000 | -6,214,000 | -7,043,000 | -9,915,000 | -10,818,000 | -12,835,000 | -8,630,000 | -7,958,000 | -5,544,000 | -14,490,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -15.0% | 11.00 | 13.00 | 15.00 | 10.00 | 11.00 | 18.00 | 25.00 | 35.00 | 47.00 | 59.00 | 68.00 | 76.00 | 100 | 115 | 131 | 128 | 140 | 186 | 210 | 236 | - |
Current Assets | -25.0% | 6.00 | 8.00 | 10.00 | 7.00 | 8.00 | 15.00 | 22.00 | 32.00 | 43.00 | 55.00 | 64.00 | 73.00 | 44.00 | 59.00 | 70.00 | 60.00 | 70.00 | 101 | 121 | 145 | 1.00 |
Cash Equivalents | -24.8% | 6.00 | 8.00 | 9.00 | 6.00 | 7.00 | 13.00 | 20.00 | 30.00 | 41.00 | 54.00 | 63.00 | 70.00 | 41.00 | 58.00 | 67.00 | 56.00 | 67.00 | 103 | 117 | 141 | - |
Net PPE | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00 | 10.00 | 11.00 | 12.00 | 12.00 | 12.00 | 13.00 | 9.00 |
Current Liabilities | -30.9% | 1.00 | 2.00 | 2.00 | 5.00 | 8.00 | 8.00 | 9.00 | 10.00 | 9.00 | 11.00 | 11.00 | 11.00 | 13.00 | 17.00 | 16.00 | 16.00 | 11.00 | 18.00 | 19.00 | 22.00 | 17.00 |
Shareholder's Equity | -12.1% | 10.00 | 11.00 | 13.00 | 5.00 | 4.00 | 10.00 | 17.00 | 25.00 | 37.00 | 48.00 | 56.00 | 65.00 | 48.00 | 59.00 | 75.00 | 66.00 | 82.00 | 98.00 | 119 | 141 | - |
Retained Earnings | -0.6% | -265 | -264 | -262 | -270 | -266 | -259 | -251 | -241 | -228 | -215 | -204 | -193 | -176 | -163 | -144 | -125 | -105 | -85.63 | -59.57 | -32.25 | - |
Additional Paid-In Capital | 0.1% | 276 | 276 | 276 | 275 | 270 | 270 | 268 | 267 | 265 | 263 | 261 | 258 | 225 | 223 | 220 | 192 | 187 | 183 | 179 | 173 | - |
Shares Outstanding | 1.0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 7.00 | - | - | - | 19.00 | - | - | - | 132 | - | - | - | 160 | - | - | - | 306 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -21.4% | -1,871 | -1,541 | -6,935 | -6,555 | -6,214 | -7,043 | -9,915 | -10,818 | -12,835 | -8,630 | -7,923 | -5,509 | -14,455 | -14,041 | -15,048 | -14,221 | -29,180 | -22,163 | -23,812 | -21,969 | -34,271 |
Share Based Compensation | 75.7% | 181 | 103 | 159 | 379 | 426 | 1,124 | 1,662 | 1,699 | 1,767 | 2,547 | 2,412 | 2,340 | 2,312 | 3,207 | 3,796 | 3,953 | 4,036 | 4,470 | 4,948 | 6,224 | 3,989 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | -7.00 | 2.00 | 1,462 | 1,436 | 3.00 | -65.00 | -1,356 | -100 | -554 | -4,247 | -1,814 |
Cashflow From Financing | - | - | - | - | - | - | 12.00 | - | 17.00 | - | 85.00 | 43.00 | 30,630 | 27.00 | 159 | 24,267 | 3,663 | 1.00 | 145 | 365 | 174,976 | 36,085 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Cost and expenses: | ||
Research and development | $ 44 | $ 572 |
General and administrative | 1,574 | 2,703 |
Total cost and expenses | 1,618 | 3,275 |
Loss from operations | (1,618) | (3,275) |
Interest and other income, net | 76 | 88 |
Net loss from continuing operations | (1,542) | (3,187) |
Discontinued operations: | ||
Loss from discontinued operations | 0 | (3,767) |
Net loss | $ (1,542) | $ (6,954) |
Net loss per share - basic and diluted | ||
Net loss per share from continuing operations, basic | $ (0.62) | $ (1.46) |
Net loss per share from discontinued operations Basic | 0 | (1.73) |
Net loss per share - basic | (0.62) | (3.2) |
Net loss per share from continuing operations, diluted | (0.62) | (1.46) |
Net loss per share from discontinued operations Diluted | 0 | (1.73) |
Net loss per share - diluted | $ (0.62) | $ (3.2) |
Weighted average shares used in calculating: | ||
Weighted average shares used in calculating net loss per share - basic | 2,494 | 2,176 |
Weighted average shares used in calculating net loss per share - diluted | 2,494 | 2,176 |
Other comprehensive loss: | ||
Net loss | $ (1,542) | $ (6,954) |
Other comprehensive loss: | ||
Foreign currency translation adjustment gain (loss) | (4) | 1 |
Comprehensive loss | $ (1,546) | $ (6,953) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,696 | $ 7,571 |
Prepaid expenses | 308 | 442 |
Other current assets | 10 | 11 |
Total current assets | 6,014 | 8,024 |
Other investment | 5,350 | 5,350 |
Total assets | 11,364 | 13,374 |
Current liabilities: | ||
Accounts payable | 741 | 1,198 |
Accrued research and development costs | 90 | 90 |
Accrued expenses and other current liabilities | 610 | 798 |
Total current liabilities | 1,441 | 2,086 |
Commitments and contingencies (Note 8) | 0 | 0 |
Stockholders' equity | ||
Preferred shares, no par value, 500,000 shares authorized and 351,037 series A convertible preferred stock issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, no par value, 20,000,000 shares authorized at March 31, 2024 and December 31, 2023; 2,710,096 and 2,645,096 shares issued at March 31, 2024 and December 31, 2023, respectively; 2,499,601 and 2,474,159 shares outstanding at March 31, 2024 and December 31, 2023, | 0 | 0 |
Paid-in capital | 275,898 | 275,717 |
Accumulated deficit | (265,959) | (264,417) |
Accumulated other comprehensive loss | (16) | (12) |
Total stockholders' equity | 9,923 | 11,288 |
Total liabilities and stockholders' equity | $ 11,364 | $ 13,374 |